The content on this site is intended for healthcare professionals only
Dr Andrew Furness speaks to ecancer about the final analysis of cohort 1A of the IOV-COM-202 study, evaluating lifileucel, a tumour-infiltrating lymphocyte (TIL) cell therapy, in combination with pembrolizumab as first-line treatment for advanced melanoma.
He reports encouraging antitumour activity, with an objective response rate of 62% and a complete response rate of 29.2% among patients receiving the specified lifileucel dose, with most responders maintaining their responses for at least 12 months.
Dr Furness explains that molecular analyses demonstrated greater persistence of tumour-derived T-cell receptors in responding patients, providing insights into the potential mechanisms underlying durable treatment responses.
He also highlights a safety profile consistent with previous experience and suggest that these findings support further investigation of lifileucel plus pembrolizumab in the ongoing phase III TILVANCE-301 trial.
You can also read the news story here.
Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma
Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM
Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone
